Month: April 2026

COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above. The virus-like particle (VLP) single-dose vaccine is the first chikungunya vaccine to receive approval in Switzerland and was approved following review of the regulatory dossier submitted in July 2025, upon the FDA and EMA approvals of the vaccine earlier in 2025. “The Swiss approval marks another important milestone in our endeavors to bring protection against chikungunya to more people and reinforces our commitment to expanding access to our vaccine globally,” said Paul Chaplin, President & CEO of Bavarian Nordic. The approval...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Transaction includes EUR 25.0M investment from EQT Life Sciences Strong additional support from high-quality, long-only and sector specialist investors Cash runway now extends into Q1 2028EINDHOVEN, the Netherlands, April 16, 2026 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence...

Liisa Pursiheimo photoLiisa Pursiheimo photoSuominen Corporation stock exchange release on April 16, 2026, at 8:45 a.m. (EEST) Suominen has appointed Liisa Pursiheimo (M.Sc., Economics and International Business, Finnish and American citizen) as Chief Human Resources Officer (CHRO) and a member of the Suominen Leadership Team, effective April 21, 2026. With decades of international leadership experience, Liisa Pursiheimo has been based in the United States for much of her career, leading global people initiatives across diverse markets and cultures. Most recently, she spent four years at SACHEM, Inc., where she served as Global Director, Human Resources. “I am pleased to welcome Liisa Pursiheimo to Suominen. Her experience spans working with international teams and stakeholders, supporting organizations through growth and transformation...

Madrid, April 16.— The certified email service of Spanish listed company Lleida.net (BME:LLN, EPA:ALLLN) has been explicitly recognized by five Audiencias Provinciales (Spain’s intermediate appellate courts, which hear appeals at the provincial level) as a valid, sufficient, and legally authoritative means of proving compliance with the MASC procedural prerequisite established by Organic Law 1/2025 on the Efficiency of the Public Justice Service. The rulings are final and not subject to ordinary appeal. The most recent of these rulings, recently issued by the Audiencia Provincial of Palma de Mallorca, helped a passenger pursue her claim for a missed flight. The Audiencias Provinciales of Navarra, Gipuzkoa, Ourense, Huelva, and Álava, as well as the aforementioned court in Palma de Mallorca, in separate rulings handed down between...

EfTEN United Property Fund earned a net profit of 106 thousand euros in March and 461 thousand euros in first quarter of 2026 (the same period last year: 706 thousand euros). The net asset value (NAV) of the fund unit was 11,95 euros at the end of March, increasing by 0,4% per month. The decrease in profit is primarily related to the fund’s investment in EfTEN Real Estate Fund AS shares, which price on the Tallinn Stock Exchange increased by 2.9% in the first quarter of 2026 compared to 4.5% in the same period in 2025. In addition, interest income from the investment in the development company Invego Uus-Järveküla OÜ decreased compared to the last year, as the development company returned the principal amount of the owner loan to the fund in full in mid-March. Invego Uus-Järveküla OÜ, a development company in which the fund has an...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) —BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB). The RIV-TARGET Phase 3 clinical trial (NCT07326540) aims to compare BV100 plus low-dose polymyxin B to Colistin plus high-dose ampicillin-sulbactam in patients with suspected HABP or VABP due to carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). The start of Phase 3 follows the successful Phase 2 study that showed an overall 50% reduction in mortality compared with best available therapy.  Global pivotal Phase 3 trial is on track to enroll last patient by the end of 2027 and will support...

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) — Skull Ridge Gold Corp. (CSE: SKUL) (“Skull Ridge” or the “Company”), further to its news release dated April 10, 2026, announces that it has repriced the terms of its previously announced non-brokered private placement financing. The Company will now issue units at a price of $0.026 per unit (previously $0.025 per unit) for gross proceeds of up to $100,000. Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share at a price of $0.05 per share for a period of five (5) years from the date of issuance. All other terms of the financing remain unchanged, including participation by the Company’s Chief Executive Officer, Karim Rayani, who has agreed to subscribe...